Lv3
240 积分 2024-01-04 加入
Integration of PSMA-Targeted Theranostics into Multidisciplinary Care for Improved Efficiencies and Patient Care
3个月前
已关闭
Intra-arterial Hepatic 177Lu-PSMA-Radioligand Therapy in Liver-Dominant Metastatic Castration-Resistant Prostate Cancer: A Case Series
4个月前
已完结
Lutetium-177 Therapy in Italy: Environmental Impact Assessment in Anticipation of Its Widespread Use in Prostate Cancer Treatment
4个月前
已完结
Harmonization of practice of release of patients after radiopharmaceutical therapy
4个月前
已完结
Durable responses to frontline 177Lu-PSMA radioligand therapy in patients with metastatic castration resistant prostate cancer (mCRPC)
4个月前
已完结
Evaluation of external radiation exposure in patients treated with 177Lu-PSMA and radiation safety assessment of the patient caregivers
4个月前
已完结
Volumetric 68 Ga- prostate-specific membrane antigen PET/computed tomography analysis of bone metastasis subtypes in prostate cancer: correlation with prostate-specific antigen and International Society of Urological Pathology grade
6个月前
已关闭
177Lu-PSMA放射性配体疗法治疗前列腺癌安全管理中国专家共识
8个月前
已完结
[Epidemiology of prostate cancer in China: an overview and clinical implication]
10个月前
已完结
皖公网安备34019202002308
